P7C3 suppresses astrocytic senescence to protect dopaminergic neurons: Implication in the mouse model of Parkinson’s disease
Open Access
- 26 July 2024
- journal article
- research article
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (7) , e14819
Abstract
Aims: Astrocytic senescence is inextricably linked to aging and neurodegenerative disorders, including Parkinson's disease (PD). P7C3 is a small, neuroprotective aminopropyl carbazole compound that exhibits anti‐inflammatory properties. However, the effects of P7C3 on astrocytic senescence in PD remain to be elucidated.Methods: An in vitro, long culture‐induced, replicative senescence cell model and a 1‐methyl‐4‐phenylpyridinium (MPP+)/rotenone‐induced premature senescence cell model were used to investigate the effects of P7C3 on astrocytic senescence. An in vivo, 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced mouse PD model was used to study the role of P7C3 in astrocytic senescence. Immunoblotting, real‐time quantitative RT‐PCR (qPCR), immunofluorescence, subcellular fractionation assays, and immunohistochemistry were utilized to confirm the effects of P7C3 on astrocytic senescence and elucidate its underlying mechanisms.Results: This study determined that P7C3 suppressed the senescence‐associated secretory phenotype (SASP) in both cell models, as demonstrated by the reduction in the critical senescence marker p16 and proinflammatory factors (IL‐6, IL‐1β, CXCL10, and MMP9) and increased laminB1 levels, implying that P7C3 inhibited replicative astrocytic senescence and MPP+/rotenone‐induced premature astrocytic senescence, Most importantly, we demonstrated that P7C3 prevented the death of dopamine (DA) neurons and reduced the behavioral deficits in the MPTP‐induced mouse model of PD, which is accompanied by a decrease in senescent astrocytes in the substantia nigra compacta (SNc). Mechanistically, P7C3 promoted Nrf2/Sirt3‐mediated mitophagy and reduced mitochondrial reactive oxygen species (mitoROS) generation, which contributed to the suppression of astrocytic senescence. Furthermore, Sirt3 deficiency obviously abolished the inhibitory effects of P7C3 on astrocytic senescence.Conclusion: This study revealed that P7C3 inhibited astrocytic senescence via increased Nrf2/Sirt3‐mediated mitophagy and suppression of mitoROS, which further protected against DA neuronal loss. These observations provide a prospective theoretical basis for P7C3 in the treatment of age‐associated neurodegenerative diseases, such as PD.Keywords
Funding Information
- National Natural Science Foundation of China (32200775)
This publication has 49 references indexed in Scilit:
- Pharmacologic rescue of motor and sensory function by the neuroprotective compound P7C3 following neonatal nerve injuryNeuroscience, 2015
- Mitochondrial effectors of cellular senescence: beyond the free radical theory of agingAging Cell, 2014
- P7C3 Neuroprotective Chemicals Block Axonal Degeneration and Preserve Function after Traumatic Brain InjuryCell Reports, 2014
- P7C3 Neuroprotective Chemicals Function by Activating the Rate-Limiting Enzyme in NAD SalvageCell, 2014
- The P7C3 class of neuroprotective compounds exerts antidepressant efficacy in mice by increasing hippocampal neurogenesisMolecular Psychiatry, 2014
- Isradipine prevents rotenone-induced intracellular calcium rise that accelerates senescence in human neuroblastoma SH-SY5Y cellsNeuroscience, 2013
- Contribution of growth differentiation factor 6-dependent cell survival to early-onset retinal dystrophiesHuman Molecular Genetics, 2013
- Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosisProceedings of the National Academy of Sciences, 2012
- Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson diseaseProceedings of the National Academy of Sciences, 2012
- Discovery of a Proneurogenic, Neuroprotective ChemicalCell, 2010